Acquisition and carriage of multidrug-resistant organisms in dogs and cats presented to small animal practices and clinics in Switzerland. by Dazio, Valentina et al.
S T ANDA RD AR T I C L E
Acquisition and carriage of multidrug-resistant organisms
in dogs and cats presented to small animal practices and clinics
in Switzerland
Valentina Dazio1 | Aurélien Nigg2 | Janne S. Schmidt3 | Michael Brilhante2,4 |
Nico Mauri6 | Stephan P. Kuster7 | Stefanie Gobeli Brawand2 |
Gertraud Schüpbach-Regula8 | Barbara Willi3 | Andrea Endimiani5 |
Vincent Perreten2 | Simone Schuller1
1Department of Clinical Veterinary Medicine,
University of Bern, Bern, Switzerland
2Institute of Veterinary Bacteriology,
University of Bern, Bern, Switzerland
3Clinic for Small Animal Internal Medicine,
University of Zurich, Zürich, Switzerland
4Graduate School of Cellular and Biomedical
Sciences, University of Bern, Bern, Switzerland
5Institute for Infectious Diseases, University of
Bern, Faculty of Medicine, Bern, Switzerland
6Tierklinik Aarau West AG, Oberentfelden,
Switzerland
7Better Together Healthcare Consulting,
Steinackerstrasse 44, Wiesendangen, Zurich,
Switzerland
8Department of Clinical Research and Public
Health, University of Bern, Bern, Switzerland
Correspondence
Simone Schuller, Vetsuisse Faculty Bern,
Länggassstrasse 128, CH-3012 Bern,
Switzerland.
Funding information
National Research Programme, Antimicrobial
Resistance of Swiss National Science
Foundation, Grant/Award Number: 177378;
Swiss Federal Food Safety and Veterinary
Office (FSVO), Grant/Award Number: 1.18.10
Abstract
Background: The emergence and spread of multidrug-resistant organisms (MDRO)
present a threat to human and animal health.
Objectives: To assess acquisition, prevalence of and risk factors for MDRO carriage
in dogs and cats presented to veterinary clinics or practices in Switzerland.
Animals: Privately owned dogs (n = 183) and cats (n = 88) presented to 4 veterinary
hospitals and 1 practice.
Methods: Prospective, longitudinal, observational study. Oronasal and rectal swabs
were collected at presentation and 69% of animals were sampled again at discharge.
Methicillin-resistant (MR) staphylococci and macrococci, cephalosporinase-, and
carbapenemase-producing (CP) Enterobacterales were isolated. Genetic relatedness
of isolates was assessed by repetitive sequence-based polymerase chain reaction and
multilocus sequence typing. Risk factors for MDRO acquisition and carriage were
analyzed based on questionnaire-derived and hospitalization data.
Results: Admission prevalence of MDRO carriage in pets was 15.5% (95% confidence
interval [CI], 11.4-20.4). The discharge prevalence and acquisition rates were 32.1%
(95% CI, 25.5-39.3) and 28.3% (95% CI, 22-35.4), respectively. Predominant hospital-
acquired isolates were extended spectrum β-lactamase-producing Escherichia coli
(ESBL-E coli; 17.3%) and β-lactamase-producing Klebsiella pneumoniae (13.7%). At 1 insti-
tution, a cluster of 24 highly genetically related CP (blaoxa181 and blaoxa48) was identified.
Multivariate analysis identified hospitalization at clinic 1 (odds ratio [OR], 5.1; 95% CI,
Abbreviations: 3GCR, third-generation cephalosporin-resistant; 3GCR-E, third-generation cephalosporin-resistant enterobacterales; CI, confidence interval; CLSI, clinical and laboratory standards
institute; CP, carbapenemase-producing; CRE, carbapenem-resistant enterobacterales; ERIC-PCR, enterobacterial repetitive intergenic consensus polymerase chain reaction; ESBL, extended
spectrum β-lactamase; ESBL-E coli, ESBL-producing Escherichia coli; ESBL-KP, ESBL-producing Klebsiella pneumoniae; EUCAST, European Committee on Antimicrobial Susceptibility Testing; ICU,
intensive care unit; IPC, infection prevention and control; IQR, interquartile range; KP, Klebsiella pneumoniae; MALDI-TOF MS, matrix-assisted laser desorption/ionization time of flight mass
spectrometry; MDR, multidrug-resistant; MDRO, multidrug-resistant organisms; MICs, minimal inhibitory concentrations; MLST, multilocus sequence typing; MR, methicillin-resistant; MRCoNS,
methicillin-resistant coagulase-negative staphylococci; MRSA, methicillin-resistant Staphylococcus aureus; MRSP, methicillin-resistant Staphylococcus pseudintermedius; OR, odds ratio; pAmpC,
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1.6-16.8) and days of hospitalization (OR 3-5 days, 4.4; 95% CI, 1.8-10.9; OR > 5 days,
6.2; 95% CI, 1.3-28.8) as risk factors for MDRO acquisition in dogs.
Conclusions: Veterinary hospitals play an important role in the selection and trans-
mission of MDRO among veterinary patients.
K E YWORD S
carbapenemase-producing enterobacterales, extended-spectrum β-lactamase, risk factors,
transmission
1 | INTRODUCTION
Emergence of multidrug-resistant organisms (MDRO) poses an impor-
tant threat to human and animal health.1 Like human hospitals, veteri-
nary hospital environments favor the selection and transmission of
MDRO because of a high density of susceptible patients and the use
of broad-spectrum antimicrobials.2 During their hospitalization, small
animals therefore may become asymptomatic carriers of MDRO or
may develop life-threatening nosocomial infections. These infections
may be difficult to treat because of resistance of MDRO to several, if
not all, commonly used classes of antimicrobials.3
Several MDRO are considered to be of particular relevance to both
human and animal health. Methicillin-resistant (MR) Staphylococcus
aureus (S aureus; MRSA) generally is isolated at low frequency from
dogs and cats,4,5 and pet owners may be the primary source.6 In con-
trast, MR Staphylococcus pseudintermedius (S pseudintermedius; MRSP)
clones are widespread in veterinary settings worldwide5,7 and show
resistance to many antibiotics licensed in veterinary medicine.5,8
Methicillin-resistant S pseudintermedius cause a wide range of infections
in dogs and cats including skin and postoperative infections.7-9 It is also
increasingly reported as cause of severe infections in humans.9 Macro-
coccus spp. (M canis; M caseolyticus) have been isolated from the skin of
healthy dogs and infection sites, and have the potential to acquire
methicillin resistance genes (mecB; mecD).10-12 Their relevance in veteri-
nary settings so far has not been evaluated in detail.
Multidrug-resistant Enterobacterales including Escherichia coli (E
coli), Klebsiella spp. and Enterobacter spp. presently are considered
highly problematic in both veterinary13,14 and human13,15 hospital set-
tings. Enterobacterales with third-generation cephalosporin resistance
(3GCR-E) are widespread16 and often display coresistance to other
classes of antibiotics including tetracyclines, sulfonamides, phenicols,
aminoglycosides, and fluoroquinolones.17,18 The use of carbapenems to
treat such infections has led to the selection of carbapenem-resistant
Enterobacterales (CRE) in human medicine,19 whereas up until very
recently, reports of carbapenem resistance have been very rare in vet-
erinary medicine.20,21 However, as molecular mechanisms of resistance
continue to evolve, the epidemiology of MDRO colonization and infec-
tion and relevant risk factors are changing.22
Our aims were to assess risk factors for prevalence and acquisi-
tion of MDRO carriage in dogs and cats presented to veterinary clinics
or practices in Switzerland and to describe relevant MDRO in veteri-
nary care settings.
2 | MATERIALS AND METHODS
2.1 | ETHICS STATEMENT
Ethical approval for collection of samples and clinical data from cats and
dogs was granted by the Veterinary Office (Ref. BE 16/18). Written owner
consent for participation in the study was obtained before enrollment.
2.2 | Study Design and Setting
This prospective multicenter longitudinal observational study was part
of a large project to assess the role of small animal clinics in the dis-
semination of MDRO (Ref FSVO 1.8.10). Dogs and cats presented to
3 large referral hospitals (clinics 1-3), 1 smaller clinic (clinic 4), and a
small practice (practice 1) across Switzerland between May and
September 2018 were enrolled sequentially regardless of their clinical
focus. Clinics 1 to 3 are large referral hospitals with an annual case-
load of approximately 6000, 12 000, and 60 000 cases, respectively.
Clinic 4 is a moderately sized small animal clinic providing a large
range of services including orthopedic surgery and practice 1 a small
practice for companion animals providing predominantly outpatient
services and routine surgery. Animals were included if they were
expected to be hospitalized for at least 48 hours, except for practice
1, where hospitalizations rarely occurred and samples therefore were
collected from dogs and cats presented for outpatient care.
2.3 | Data collection
2.3.1 | Questionnaires
At presentation, owners were asked to fill out a questionnaire that
contained questions regarding the animal's origin, lifestyle, living
environment, preventative health care, diet, current or previous
medical treatments, travel history, and contact with other animals,
including farm animals. The questionnaire also contained owner-
centered questions (results not included here). The questionnaire
was available in paper format and via an online link (Supplemental
data Questionnaire). Study data were collected and managed using
the Research Electronic Data Capture system (REDCap) hosted at
the University of Bern.23,24
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2.3.2 | Animals
Demographic data including breed, age, weight, sex, neuter status, hos-
pitalizations, and treatments within the past 12 months were recorded
for all enrolled animals. Clinical diagnoses and hospitalization data
including admission ward, clinical problems or diagnoses, duration of
hospitalization, days in intensive care unit (ICU), medical interventions,
and treatments including antimicrobial treatments were extracted from
the medical records of dogs and cats hospitalized at the 2 large univer-
sity clinics only (clinics 1 and 2), where the most cases were enrolled.
2.3.3 | Sampling
Rectal and oronasal swabs were collected from dogs and cats within
the first 6 hours of admission and again on the day of discharge using
dry sterile swabs with Amies transport medium (Sarstedt AG & Co. KG,
Nümbrecht, Germany). Rectal swabs were inserted 1 to 2 cm into the
rectum and rotated gently until fecal material adhered to the swab. In
dogs, nasal swabs were gently inserted in 1 naris and rotated; the same
swab was then introduced in to the mouth lateral to the tongue. In cats,
small dogs, and uncooperative animals, the swab was only inserted
orally. Swabs were stored for a maximum of 5 days at 4C or 2 days at
ambient temperature and then sent by batch to the laboratory.
2.3.4 | Isolation and identification of bacteria
Rectal swabs and fecal samples were tested for the presence of
Gram-negative MDRO as previously described.25,26 Swabs were
placed into 5 mL of nonselective Luria-Bertani (LB) enrichment broth
at 37C for 24 hours. A loopful of the culture was then streaked on
ChromID extended spectrum β-lactamase (ESBL) plates to select for
3GCR-E, or ChromID OXA-48 and ChromID CARBA plates
(BioMérieux SA, Marcy-l'Étoile, France), to select for CRE. Plates were
incubated at 37C for 24 hours under aerobic conditions. Colonies
were subcultivated onto tryptone soy agar plates containing 5% sheep
blood (TSA-S; Becton & Dickinson Company, Franklin Lakes, New Jer-
sey). Isolates were identified to the species level by using the matrix-
assisted laser desorption/ionization time-of-flight mass spectrometry
(MALDI-TOF MS; Bruker Daltonics GmbH, Bremen, Germany).
Carbapenemase production was detected using the Blue-Carba test
(BCT).27 Oronasal swabs were tested for the presence of MR staphy-
lococci and macrococci using a 2-step selective enrichment28 followed
by selection on selective agar (BBL CHROMagar MRSA II, Becton,
Dickinson and Company, New Jersey) at 37C for 24 hours.
2.3.5 | Antimicrobial susceptibility testing
Minimal inhibitory concentrations (MICs) of antimicrobials were
determined by broth microdilution using Sensititre EUST, EUVSEC,
EUVSEC2, and GNX2F plates (Thermo Fisher Scientific, Waltham,
Massachusetts). For Gram-negative bacteria, 14 antibiotics were tested
(Thermo Fisher Scientific) following the guidelines of the European
Committee on Antimicrobial Susceptibility Testing (EUCAST).29 Results
were interpreted using the EUCAST criteria, except for nalidixic acid,
sulfamethoxazole, and tetracycline, for which the criteria from the Clini-
cal and Laboratory Standards Institute (CLSI) were used.30 Extended-
spectrum β-lactamase and carbapenemase genes were identified using
the CT103XL microarray (Check-Points, Wageningen, The Nether-
lands).31 Before whole genome sequencing (WGS), carbapenemase-
producing (CP) isolates were tested for the presence of blaOXA-48-like
genes by polymerase chain reaction (PCR).32 The MR genes mecA,
mecB, and mecD were identified by PCR as previously described.33-35
2.3.6 | REP-PCR and whole-genome sequencing
Genetic relationships and clonality among isolates of the same species
were determined by repetitive element palindromic polymerase chain
reaction (REP-PCR) or enterobacterial repetitive intergenic consensus-
polymerase chain reaction (ERIC-PCR)36,37 and by multilocus sequence
typing (MLST). For MRSA, MRSP, methicillin-resistant coagulase-negative
staphylococci (MRCoNS), and MR Macrococcus spp., the corresponding
schemes published in the pubMLST database (https://pubmlst.org/
databases/) were used and for colistin-resistant (COL-R), ESBL-produc-
ing, and CP Enterobacterales, the Center for Genomic Epidemiology
database was used (http://www.genomicepidemiology.org/).
Whole genome sequencing was used to confirm the identity of
selected isolates and the presence of specific resistance genes. Parts
of these analyses have been reported previously.26
2.3.7 | Data analysis and statistical methods
Statistical analysis was performed using the NCSS program (NCSS11
Statistical Software. 2016. NCSS, LLC, Kaysville, Utah. ncss.com/
software/ncss). Post hoc sample size calculations were performed
using the online calculator Epitools (https://epitools.ausvet.com.au).
The overall prevalence of MDRO carriage in dogs and cats at
admission and discharge and the rate of MDRO acquisition during
hospitalization were estimated with a 95% confidence interval (CI).
Acquisition was defined as the presence of a new or a genetically
unrelated MDRO in discharge samples. Persistence was defined as
isolation of MDRO with matching molecular profiles (REP-PCR, WGS)
using repeated samples from the same individual.
Associations between MDRO carriage at admission and
questionnaire-derived variables, as well as associations between MDRO
acquisition during hospitalization and hospitalization data, were exam-
ined using univariate and multivariate logistic regression analyses. First,
univariate analysis was performed for all independent variables to
assess suitability of inclusion into the multivariate regression model.
Variables with a P-value of <.1 were included in the full models. The
final model of each multivariate analysis was achieved by backward
stepwise elimination, including assessment of interaction and
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confounding. Variables were kept in the final model if the P-value was
<.05 or if removing the variable changed the effect of another risk fac-
tor by >20%. Odds ratios (OR) and 95% CIs were reported; values were
considered significant if the 95% CI of the OR did not include 1.
3 | RESULTS
3.1 | Study population
A total of 271 animals, including 183 (67.5%) dogs and 88 (32.5%)
cats, were sampled at presentation and 187 (69%) animals, including
124 (66.3%) dogs and 63 (33.7%) cats, were sampled again at dis-
charge. Most animals (221/271; 81.5%) were enrolled at clinics 1 and
2 (Supplemental Table 1).
The median age of dogs was 7 years (interquartile range [IQR],
3-9 years) and the median weight was 14.4 kg (IQR, 7.1-28.4 kg).
There were 86 females (28 intact/58 neutered) and 97 males
(36 intact/61 neutered). The majority of dogs (155/183, 85.7%) were
purebred of 68 different breeds, the most frequent being Labrador
Retriever (6.6%), Jack Russell Terrier (5.5%), Yorkshire Terrier (4.4%),
French Bulldog (3.9%), and Chihuahua (3.9%).
Cats had a median age of 6 years (IQR, 2-11 years) and a median
weight of 4.3 kg (IQR, 3.6-5.1). There were 39 neutered females and
49 males (5 intact/44 neutered). The most common breeds were
European Shorthair (68.2%), Maine Coon (11.4%), and Ragdoll (4.6%).
Questionnaire-derived lifestyle data and hospitalization and treat-
ment details of cats and dogs included in the study are shown in Sup-
plemental Tables 2 to 5. For organizational reasons, most dogs and cats
were recruited from the emergency services of the participating hospi-
tals. In dogs, the most common disease groups were neurologic, gastro-
intestinal, orthopedic, and neoplastic, whereas in cats gastrointestinal,
orthopedic, and urinary tract disease groups were most common.
Although 154 (82.4%) animals had been hospitalized ≥48 hours
according to inclusion criteria, 33 (17.6%) were in the hospital between
7 and 47 hours only, resulting in a median duration of hospitalization of
2 days (IQR, 2; range, 0-14 days). This diversion from initial inclusion
criteria resulted from unexpected early discharges or death and a loos-
ening of inclusion criteria to increase enrollment numbers. It led to the
observation that some animals seemingly acquired MDRO as early as
24 hours after admission (2 cases). The majority of dogs (78/152,
51.3%) and cats (42/77, 54.6%) were treated with antimicrobials during
their hospitalization, but none of them received carbapenems.
3.2 | Prevalence of MDRO carriage at presentation
The overall estimated admission prevalence of MDRO carriage was
15.5% (95% CI, 11.4-20.4) with 18% (33/183; 95% CI, 12.8-24.4) of
sampled dogs and 10.2% (9/88; 95% CI, 4.8-18.5) of sampled cats car-
rying MDRO. The prevalence varied among the 5 veterinary care facili-
ties and was estimated at 14% (95% CI, 8.9-20.6) in clinic 1, 9.9% (95%
CI, 4.1-19.3) in clinic 2, 7.7% (95% CI, 0.2-36) in clinic 3, 0% (95% CI,
0-41) in clinic 4, and 43.3% (95% Cl, 25.5-62.6) in the outpatient popu-
lation at practice 1. The numbers of patients enrolled in each clinic and
the proportions of MDRO-positive cases are shown in Figure 1.
Of the 271 animals, 1 variety of MDRO strain was isolated in
42 animals and 1 cat and 1 dog carried an ESBL-producing E coli
(ESBL-E coli) in addition to a MR Staphylococcus warneri (S warneri) or
a MR Staphylococcus haemolyticus (S haemolyticus).
The numbers of MDRO isolated in each clinic or practice at
admission are shown in Supplemental Table 1. Third-generation
cephalosporin-resistant E coli predominated, accounting for 33.3% of
all isolates. Methicillin-resistant Staphylococcus aureus only was iso-
lated in 1 cat, and MRSP in none of the animals. Methicillin-resistant
coagulase-negative staphylococci were isolated from 9.6% of the ani-
mals and were predominately found in 1 practice, where MR S warneri
was isolated from nearly one-third (9/30) of the sampled animals. At
presentation, MR macrococci were isolated only in 1.1% of cases. The
numbers of MDRO isolated at presentation are shown in Figure 2.
F IGURE 1 Total number of animals
tested at presentation to (P) and
discharge from (D) participating clinics/
practice. Proportions of MDRO-positive
animals are indicated above the columns.
MDRO, multidrug-resistant organisms
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3.3 | Prevalence MDRO carriage at discharge and
acquisition rate
The overall numbers of MDRO isolated at discharge are shown in
Figure 2. The numbers of MDRO isolated in each clinic are shown in
Supplemental Table 1. Sixty animals (26.7% cats; 73.3% dogs) carried
MDRO at discharge, corresponding to an overall discharge prevalence
of 32.1% (95% CI, 25.5-39.3). The MDRO discharge prevalence for cats
was 25.4% (95% CI, 15.3-38) and for dogs 35.5% (95% CI, 27.1-44.6).
Of the 42 animals that carried MDRO at admission, 11.9% (5/42;
95% CI, 4-25.5) carried a genetically related strain and 16.7% (7/42;
95% CI, 7-31.4) a genetically unrelated strain at discharge. In 19% of
animals (8/42; 95% CI, 8.6-34.1), no MDRO was isolated at discharge,
and 52.4% (22/42; 95% CI, 36.4-68) either were outpatients (practice
1; n = 15) or could not be resampled at discharge because of unex-
pected early discharge, death, or withdrawal from the study.
The overall rate of MDRO acquisition was 28.3% (95% CI, 22-35.4):
20.6% (95% CI, 11.5-33) for cats and 32.3% (95% CI, 24.1-41.2) for
dogs. Discharge prevalence and acquisition rates varied considerably
among care facilities with clinic 1 showing a particularly high rate of
MDRO acquisition (39.1%; 95% CI, 29.9-48.9) compared with clinic
2 (12.1%; 95% CI, 5-23.3), clinic 3 (25%; 95% CI, 5.48-57.2), and clinic
4 (0%; 95% CI, 0-41).
The most common hospital-acquired isolates were 3GCR-E coli and
3GCR-K pneumoniae (KP) isolated from 15% (29/187) and 12.3%
(23/187) of animals. One dog (0.5%) acquired MRSP and 8% of the ani-
mals (15/187) MRCoNS. In clinic 1, in-hospital acquisition of 3GCR-E
coli, 3GCR-KP, and MRCoNS was particularly frequent.
3.4 | Antimicrobial resistance profiles
Resistance profiles of all isolates are shown in Supplemental Tables 6
to 9. Third-generation cephalosporin-resistant-E coli producing either
ESBL (CTX-M-1/−3/−15, CTX-M-9/−14, CTX-M-1) or plasmid-
encoded AmpC (pAmpC; CMY-42; CMY-2-like) predominated, making
up 84% of all E coli isolates (Supplemental Table 6).
Twenty-two E coli isolates from clinic 1 displayed similar antimi-
crobial resistance patterns and a common blaOXA-181 carbapenemase
gene. One further E. coli isolate (101.2) from clinic 1 carried a blaOXA-
48 carbapenemase gene. This isolate had MICs below the resistance
breakpoint set by EUCAST for meropenem, but was resistant to
ertapenem. Two E. coli isolates producing NDM-5 carbapenemase
were isolated at clinic 2. These isolates were broadly resistant includ-
ing resistance to meropenem. All isolates were sensitive to colistin.
The numbers and proportions of E coli isolates resistant to the tested
antimicrobials are shown in Table 1.
The majority of KP were of the CTX-M-1/-3/-15 ESBL and
DHA-1 pAmpC subtypes and 1 isolate from clinic 1 (142.2) pos-
sessed the blaOXA-48 carbapenemase gene (Supplemental Table 7).
Enterobacter cloacae (E cloacae) isolates were resistant to several
classes of antimicrobials (Table 1; Supplemental Table 8).
The resistance profiles of MR Gram-positive isolates are shown in
Supplemental Table 9. The 2 MRSA isolates (carried at admission and dis-
charge by the same animal) carried the mecA gene and showed resistance
to penicillin, cefotaxime, and ciprofloxacin. One M caseolyticus isolate
(31.2) contained the mecD gene and showed resistance to 5 different clas-
ses of antimicrobials.
3.5 | Molecular relatedness of MDRO
The clonality of all isolates is listed in Supplemental Tables 6 to 9. Overall,
3GCR-E coli isolates were diverse, belonging to 24 different phylogenetic
groups, with the exception of a cluster of 24 ST410 CMY-42 isolates
from clinic 1, which displayed similar antimicrobial resistance patterns
and a common blaOXA-181 carbapenemase. The detailed molecular char-
acterization of this cluster of isolates has been reported recently.26
Two carbapenem-resistant ST167 E coli isolates were obtained
from clinic 2. The two isolates shared the blaNDM-5 gene and were
F IGURE 2 Number of
multidrug-resistant organisms
isolated from dogs and cats at
presentation to and discharge
from 3 veterinary clinics and





Macrococcus; E, Enterococcus; E
coli, Escherichia coli; K
pneumoniae, Klebsiella pneumoniae
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highly genetically related. The detailed molecular characterization of
these strains has been reported.26
Of the 26 3GCR-KP isolates, 20 expressed CTX-M-1/-3/-15 and
7 DHA-1 ß-lactamases. All isolates showed close genetic relatedness
belonging to REP-PCR group A. Among animals hospitalized in clinic
1, a cluster of 10 isolates (CTX-M-1/-3/-15) with similar antimicrobial
resistance pattern was identified. Three K pneumoniae isolates from
clinic 2 resembled each other in terms of ESBL resistance type and anti-
microbial resistance pattern. One single KP isolated at discharge from a
dog from clinic 1 carried a carbapenemase-encoding gene (blaOXA48).
The MDR E. cloacae isolates belonged to REP-PCR group C, with
the exception of 1 isolate from clinic 2, that was typed as REP-PCR
group E. Two isolates from clinic 1 (REP-group C) shared a similar anti-
biotic resistance profile and were found in 2 dogs, which had been
admitted to clinic 1 by the emergency service on 2 consecutive days.
3.6 | Risk factors for MDRO carriage in dogs
and cats
The questionnaire-derived variables included in the risk factor analysis
for MDRO carriage at admission for dogs and cats are shown in
Supplemental Tables 2 and 3. Univariate analysis identified antimicro-
bial treatment before admission as a significant risk factor for MDRO
carriage in dogs (OR, 2.7; 95% CI, 1.2-5.9; P = .01), but not in cats. Of
the 7 cats fed a so-called Bones and Raw Food (BARF) diet, 3 were
carrying MDRO at presentation and this association was significant in
the univariate analysis (OR, 7.3; 95% CI, 1.2-45; P = .04).
The variables included in the risk factor analysis for in-hospital
MDRO acquisition in dogs and cats are shown in Supplemental
Tables 4 and 5. Univariate analysis showed the following significant
associations for MDRO acquisition during hospitalization: hospitaliza-
tion at clinic 1 (dogs OR, 4.4; 95% CI, 1.4-13.8; cats OR, 5.1; 95% CI,
1.2-21.7), esophageal feeding tube (esophagostomy or
nasoesophageal) placement in cats (OR, 8; 95% CI, 1.3-50.8), days of
hospitalization in dogs (OR 3-5 days, 3.7; 95% CI, 1.6-8.6;
OR > 5 days, 5.3; 95% CI, 1.2-22.5), and administration of
buprenorphine in dogs (OR, 4.2; 95% CI, 1.8-10.1). The administration
of antimicrobials during hospitalization did not increase the odds of
becoming MDRO carriers in the population of cats but increased it in
the population of dogs (OR, 2.5; 95% CI, 1.1-5.7).
Multivariate analysis confirmed hospitalization at clinic 1 (OR, 5.1;
95% CI, 1.6-16.8) and days of hospitalization (OR 3-5 days, 4.4; 95%
CI, 1.8-10.9; OR > 5 days, 6.2; 95% CI, 1.3-28.8) as risk factors for
MDRO acquisition in dogs.
4 | DISCUSSION
Our results identified acquisition of MDRO in approximately one-third of
cats and dogs treated at veterinary referral hospitals. Although 1 clinic
showed a particularly high acquisition rate, MDRO acquisition was docu-
mented in all but 1 of the participating clinics. Of 180 animals hospitalized
at referral clinics, 49 (27.2%) were discharged carrying at least 1 MDR
Enterobacterales, nearly half of which expressed carbapenemases. This
finding represents a very worrisome development, because ongoing colo-
nization of these animals likely contributes to the dissemination of MDRO
in the community.
The overall admission prevalence of 15.5% was calculated including
all dogs and cats that carried Gram-positive MR, Gram-negative 3GCR
isolates, or both across all 5 participating clinics and practices. In most
studies, prevalence in healthy dogs and cats or veterinary-visiting animals
is limited to MDR E coli or MDR Enterobacterales with admission preva-
lence of 10.7% to 24.8% for dogs,13,38-40 1.4% to 15% for cats,38,40 and
7% to 8.6% for both.41,42 Studies that examined colonization with MR
Gram-positives5,41 often exclude MRCoNS because of their questionable
clinical relevance as pathogens.43 Considering the methodical differences
across different studies, the admission prevalence found in our cohort
was similar to what has been reported previously.
Third-generation cephalosporin-resistant E coli were the most
common isolates found at presentation (34% of all MDRO isolates),
suggesting that these bacteria may already be part of the gut flora of a
large proportion of the small animal referral population in Switzerland.
The 3GCR-E coli isolated at admission were diverse, including pAmpC
(CMY-42, CMY-2-like) and ESBL (CTX-M-1/-3/-15, CTX-M-9/-14, and
TABLE 1 Resistance of third-generation cephalosporin-resistant E
coli, K pneumoniae, and Enterobacter spp. isolated from admission and











Ampicillin 50 (100) 26 (100) 8 (100)
Cefotaxime 49 (98) 25 (96.2) 7 (87.5)
Ceftazidime 41 (82) 23 (88.5) 8 (100)
Meropenem 2 (4) 0 (0) 0 (0)
Sulfamethoxazole 24 (48) 24 (92) 7 (87.5)
Trimetoprim 24 (48) 22 (84.6) 5 (62.5)
Ciprofloxacin 32 (64) 24 (92) 4 (50)
Tetracyclin 22 (44) 16 (61.5) 5 (62.5)
Azitromycin 3 (6) 6 (23.1) NI
Nalidixic acid NI 26 (100) NI
Chloramphenicol 11 (22) 7 (26.9) 6 (75)
Gentamycin 13 (26) 18 (69.2) 5 (62.5)
Colistin 0 (0) 0 (0) 0 (0)
Tigecycline 0 (0) 0 (0) 0 (0)
Note: Minimal inhibitory concentrations (MIC) were interpreted using the
criteria of the European Committee on Antimicrobial Susceptibility
Testing27 except for nalidixic acid, sulfamethoxazole, and tetracycline, for
which the criteria from the Clinical and Laboratory Standards Institute
were used.28 No MIC was available for azithromycin; therefore, an MIC of
>64 mg/L was tentatively used. Data are reported as No. (%) of isolates.
NI indicates the minimum inhibitory concentrations of the antimicrobials
that were not interpreted. Numbers are given in bold when ≥50% of
isolates showed resistance.
Abbreviations: E coli, Escherichia coli; K pneumoniae, Klebsiella pneumoniae.
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CTX-M-1) genotypes. These genotypes are found in up to 10% of the
Swiss human population44 and also have been isolated from urban birds
(CTX-M-1, CTX-M-15),45 chicken meat (CMY-2, CTX-M-1),46 and pet
food (CTX-M-1, CTX-M-3, and CTX-M-15).47 A large percentage of
3GCR-E coli isolates displayed additional resistance to other classes of
antimicrobials; notably, two-thirds of the isolates were resistant to tri-
methoprim/sulfamethoxazole (TMP-S), 53.3% to tetracyclines and 26.7%
to fluoroquinolones, aminoglycosides, or both. Carbapenem resistance at
admission only was detected in 1 E. coli strain isolated from a dog. This
dog had not been treated with antimicrobials before presentation and
had never been presented at the clinic before the admission date.26
At admission, carriage of MRSA, MRSP, or macrococci was very
rare in this cohort of cats and dogs, which is in agreement with
some41,48 but not all recent studies.7,49 In contrast, there was a high
rate of isolation of MRCoNS (S warneri; S haemolyticus; ERIC-PCR group
D) in the outpatient population of practice 1. As previously reported,
sampling of the practice environment and staff in this practice identi-
fied contamination of 3/37 sampling sites with S haemolyticus (ST49;
mecA).25 Based on these results, it cannot be excluded that MRCoNS
were acquired in the practice. However, a high prevalence of carriage
of MRCoNS also has been documented in a population of healthy
nonveterinary-visiting Labrador retrievers in the United Kingdom,
which had no contact with veterinary practice environments and had
not received antimicrobial treatments,50 thus suggesting sources of
acquisition outside of veterinary care. Beyond their role as opportunis-
tic pathogens, MRCoNS can act as reservoirs for resistance genes and a
source of infection or colonization of in-contact humans.43
Dogs having received systemic antimicrobial treatments before
presentation had increased odds of carrying MDRO upon admission.
This finding is in agreement with other studies in pets,51 farm
animals,52 and humans,53,54 suggesting that systemic antimicrobial
treatments select for MDR bacteria within the host microbiome. The
fact most animals presented at referral institutions already have been
treated with antimicrobials puts these institutions at increased risk of
continuously having MDRO introduced into their hospital environ-
ments.2 Screening of patients with risk factors for MDRO carriage in
large referral institutions therefore should be considered part of
routine animal admission procedures.
An additional risk factor for MDRO carriage at presentation in
cats was a BARF diet. Extended spectrum β-lactamase-producing E
coli and other MDRO have been isolated from farm animals at
slaughter,55 as well as from fresh meat56 and milk,57 and the associa-
tion between BARF and MDRO colonization, in particular by MDR
Enterobacterales, previously has been described in both cats58,59and
dogs.38,59 The feeding of a BARF diet to dogs and cats therefore
should be discouraged.
Acquisition of MDRO was common in referral hospitals in our
study and still amounted to 12.1% in the institution with the lowest
acquisition rate among all 3 institutions. In a previous study, the hos-
pital acquisition rate for MDR E coli was reported at 6.8%.41 In com-
parison, the acquisition rate of MDR E coli in this set of hospitals
ranged between 6.9% and 20.9% and thus was markedly higher in
some of the hospitals than previously reported.
In clinic 1, the MDRO acquisition rate was strikingly high (39.1%),
predominantly because of the acquisition of 3GCR-E coli and 3GCR-KP.
More than half of E coli isolates (26/50) and 1/26 K pneumoniae isolates
carried carbapenemase-encoding genes (blaoxa-181, blaoxa-48, blaNDM5).
The closely related blaoxa-181, blaoxa-48 genes have been associated with
low-level resistance to carbapenems and may go undetected during
routine diagnostic testing if the EUCAST screening breakpoints for
meropenem or imipenem are not used.60 As carbapenemase producers
regrettably may become more widespread in veterinary medicine, it is
important that veterinary bacteriology laboratories extend their routine
diagnostic testing to the identification of these isolates, in particular in
view of their public health relevance.32
The molecular relatedness and mobile genetic elements of a clus-
ter of 21 E. coli isolates (ST410; blaOXA-181) from clinic 1 subsequently
were analyzed further using WGS and shown to be clonal, displaying
shared plasmidic resistance genes.26 The same E coli strain could be
linked to the transitory colonization of 1 staff member,61 and a closely
related E coli strain (ST410, blaCMY-42, blaOXA-181) was found in 1 envi-
ronmental sample from clinic 1.25 Overall, these findings are indicative
of nosocomial spread.
Interestingly, in this clinic, the environment was also shown to be
extensively contaminated with K pneumoniae (ST11; blaOXA-48, blaDHA-1)
and MRSP (ST551; mecA).25 A closely related KP strain (ST11; blaOXA-48)
was isolated only from 1 cat. The MRSP was only acquired by 1 dog dur-
ing hospitalization and was unrelated (ST1337;mecA).
As a consequence of the high acquisition rate, hospitalization at
clinic 1 represented a substantial risk factor for MDRO acquisition. In
this institution, 30% of environmental sampling sites were positive for
MDRO, the infrastructure for hand hygiene was outdated, cleaning
and disinfection protocols had not been updated for some time, and
the wearing of gloves had largely replaced standard hand disinfec-
tion.25 These factors likely contributed to the spread of MDRO in this
institution and have since been addressed.
In clinic 2, acquisition of CP E coli (ST167; blaNDM-5) also occurred,
and closely genetically related strains were carried by staff members,61
but the MDRO acquisition rate (12.1%) was markedly lower than in
clinic 1. In clinic 2, stringent infection prevention and control (IPC)
blaNDM-5 standards, reflected by a high IPC score, were in place and only
8% of environmental sampling sites identified MDRO colonization.25
Additional risk factors for MDRO acquisition from the univariate
analysis were days of hospitalization, administration of buprenorphine,
and use of antimicrobials during hospitalization in dogs. Of these, only
days of hospitalization remained significant in the multivariate model.
This finding concurs with what has been reported previously in pets41,62
and humans.62,63
The high rate of isolation of CP organisms was unexpected,
because carbapenems are not used in clinics 1 and 2.64,65 However,
the restricted use of a specific class of antimicrobials itself is not suffi-
cient to avoid emergence of relative resistance, because the selection
pressure exerted by the use of any broad-spectrum antimicrobial may
co-select for carbapenem resistance.66 Antimicrobial prescriptions for
selected conditions in dogs and cats in 2016 recently have been
reported, and these studies included prescription data from clinics
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1 and 2.64,65 Comparison of the data subsets from these 2 clinics did
not identify any substantial differences in the frequency or appropri-
ateness of antimicrobial prescriptions (data not shown). Therefore, dif-
ferences in IPC standards are more likely the driving force behind the
differences in environmental colonization25 and MDRO acquisition
between the 2 clinics. Nonetheless, besides active surveillance of
resistance and implementation of stringent environmental and hand
hygiene protocols, antimicrobial stewardship plays an important role
in limiting the emergence and spread of MDRO in referral hospitals.
Limitations of our study include the limited number of animals
enrolled, which might have led to a failure to detect significant risk
factors for MDRO carriage because of type II error. Furthermore, the
statistical power of the comparison of acquisition rates among clinics
was limited because of unequal sample sizes.
Differences in sample storage conditions (4C vs room temper-
ature) and duration (1-5 days) may have influenced the likelihood
of MDRO recovery. Although some investigators have found that
samples could be stored at room temperature or at 4C for up to
14 days without a decrease in recovery,67 others have described
decreased recovery of bacteria after storage at 4C for 1 or
4 weeks using direct plating without prior enrichment.68 We are
confident however that the short storage times and use of enrich-
ment culture in our study would have minimized any potential
effect of storage at 4C.
In conclusion, screening of dogs and cats presented to veterinary
clinics in Switzerland identified an unexpectedly high rate of acquisi-
tion of 3GCR-Enterobacterales, including strains with carbapenemase
resistance. These findings emphasize that small animal veterinary
clinics may contribute to the selection and spread of MDRO. Active
surveillance of resistance, stringent IPC, and antimicrobial stewardship
are key elements to ensure patient safety and decrease the public
health risk.
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